Geode Capital Management LLC Has $8.31 Million Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Geode Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 5.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,667,515 shares of the company’s stock after buying an additional 90,543 shares during the quarter. Geode Capital Management LLC owned approximately 1.83% of Aquestive Therapeutics worth $8,306,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of AQST. Barclays PLC raised its stake in Aquestive Therapeutics by 285.4% in the 3rd quarter. Barclays PLC now owns 99,312 shares of the company’s stock valued at $495,000 after acquiring an additional 73,542 shares during the period. Wellington Management Group LLP bought a new position in Aquestive Therapeutics during the third quarter worth $922,000. State Street Corp increased its holdings in shares of Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after purchasing an additional 512,682 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics in the third quarter valued at about $995,000. Finally, MetLife Investment Management LLC lifted its stake in shares of Aquestive Therapeutics by 86.3% during the 3rd quarter. MetLife Investment Management LLC now owns 36,096 shares of the company’s stock worth $180,000 after buying an additional 16,716 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on AQST shares. Leerink Partners boosted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, December 20th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Price Performance

Shares of AQST opened at $3.67 on Friday. The company has a market capitalization of $334.62 million, a price-to-earnings ratio of -8.16 and a beta of 2.63. Aquestive Therapeutics, Inc. has a 1 year low of $1.98 and a 1 year high of $6.23. The business has a 50-day moving average of $4.45 and a 200-day moving average of $4.11.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the firm posted ($0.03) EPS. As a group, sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.